Discordance Between Physicians' Estimation of Patient Cardiovascular Risk and Use of Evidence-Based Medical Therapy

American Journal of Cardiology

Volumn 102, Issue 9, 2008, Pages 1142-1145

  Tsang, Jennifer L Y ^a   Mendelsohn, Aurora ^b   Tan, Mary K K ^b   Hackam, Daniel G ^c   Leiter, Lawrence A ^a   Fitchett, David ^a,b   Lin, Peter J ^b,d   Grima, Etienne ^b   Langer, Anatoly ^a,b   Goodman, Shaun G ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CANADIAN HEART RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DISEASE REGISTRY; EVIDENCE BASED MEDICINE; HUMAN; OUTPATIENT; PATIENT ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL COMPETENCE; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLATELET AGGREGATION INHIBITORS; PROFESSIONAL PRACTICE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 54549097031     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.06.037     Document Type: Article

References (13)

1. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47 (2006) 2130-2139
2. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., Franklin B.A., Goldstein L.B., Greenland P., Grundy S.M., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
3. Hackam D.G., Tan M.K., Honos G.N., Leiter L.A., Langer A., Goodman S.G., and Vascular Protection Registry Investigators. How does the prognosis of diabetes compare with that of established vascular disease?. Insights from the Canadian Vascular Protection (VP) Registry. Am Heart J 148 (2004) 1028-1033
4. Hackam D.G., Tan M.K., Lin P.J., Mehta P.G., Jaffer S., Kates M.L., Oh M., Grima E.A., Langer A., and Goodman S.G. Vascular Protection Registry and Guideline Oriented Approach in Lipid Lowering Registry Investigators. Supporting a call to action for peripheral vascular disease: insights from two prospective registries. J Vasc Surg 44 (2006) 776-781
5. Yan A.T., Yan R.T., Tan M., Hackam D.G., Leblanc K.L., Kertland H., Tsang J.L., Jaffer S., Kates M.L., Leiter L.A., et al., Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 119 (2006) 676-683
6. Hackam D.G., Leiter L.A., Yan A.T., Yan R.T., Mendelsohn A., Tan M., Zavodni L., Chen R., Tsang J.L., Kundi A., et al. Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol 23 (2007) 1124-1130
7. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
8. Majumdar S.R., McAlister F.A., and Furberg C.D. From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol 43 (2004) 1738-1742
9. Kiefe C.I., Allison J.J., Williams O.D., Person S.D., Weaver M.T., and Weissman N.W. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA 285 (2001) 2871-2879
10. Soumerai S.B., McLaughlin T.J., Gurwitz J.H., Guadagnoli E., Hauptman P.J., Borbas C., Morris N., McLaughlin B., Gao X., Willison D.J., Asinger R., and Gobel F. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA 279 (1998) 1358-1363
11. Tsuyuki R.T., Johnson J.A., Teo K.K., Simpson S.H., Ackman M.L., Biggs R.S., Cave A., Chang W.C., Dzavik V., Farris K.B., et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 162 (2002) 1149-1155
12. Hunt D.L., Haynes R.B., Hanna S.E., and Smith K. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review. JAMA 280 (1998) 1339-1346
13. Lee C.H., Tan M., Yan A.T., Yan R.T., Fitchett D., Grima E.A., Langer A., Goodman S.G., and Canadian Acute Coronary Syndromes II (ACS II) Registry Investigators. The utilization of cardiac catheterization for non-ST-segment elevation acute coronary syndromes according to initial risk: reasons why physicians choose not to refer their patients. Arch Intern Med 168 (2008) 291-296